DIB 1.0 g Vaginal Delivery System for Cattle

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

지금 구매하세요

Download 제품 특성 요약 (SPC)
05-06-2021
Download 공공 평가 보고서 (PAR)
25-02-2022
Download DSU (DSU)
09-06-2023

유효 성분:

Progesterone

제공처:

Syn Vet-Pharma Ireland Limited

ATC 코드:

QG03DA04

INN (국제 이름):

Progesterone

복용량:

1.0 gram(s)

약제 형태:

Vaginal delivery system

처방전 유형:

POM: Prescription Only Medicine as defined in relevant national legislation

치료 영역:

progesterone

승인 상태:

Authorised

승인 날짜:

2021-06-04

제품 특성 요약

                                Health Products Regulatory Authority
04 June 2021
CRN00CF35
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
DIB 1.0 g Vaginal Delivery System for Cattle
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
​
Each vaginal delivery system contains:
​
​
​
ACTIVE SUBSTANCE:
​
​
​
Progesterone
​1.0
g​
​
EXCIPIENTS:
​
​
​
For the full list of excipients, see section 6.1.
​
​
3 PHARMACEUTICAL FORM
Vaginal delivery system.
A white winged "V" shape device covered in progesterone-impregnated
silicone, fitted with a green nylon tail to enable
removal.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle (cows and heifers).
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the control of the oestrous cycle in cycling cows and heifers used
in combination with prostaglandin F2α (PGF2α) or
analogue, including synchronisation of oestrus, e.g. of donor and
recipient animals for embryo transfer.
For induction and synchronisation of oestrus in fixed time artificial
insemination (FTAI) protocols:
- In cycling cows and heifers: used in combination with PGF2α or
analogue.
- In cycling and non-cycling cows and heifers used in combination with
Gonadotropin releasing hormone (GnRH) or analogue
and PGF2α or analogue.
- In non-cycling cows, used in combination with PGF2α or analogue and
equine chorionic gonadotrophin (eCG).
4.3 CONTRAINDICATIONS
Do not use in sexually immature heifers or in females with abnormal
genital tracts e.g. freemartins.
Do not use in animals presenting with infectious or non-infectious
diseases of the genital tract.
Do not use within the first 35 days after calving.
Do not use in pregnant cattle. See section 4.7
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
The progesterone treatment alone, according to dosage regimen
proposed, is not sufficient to induce oestrus and ovulation in
all cycling females. Progesterone based breeding protocols are
reproduction management tools and should not replace
adequate feeding and general health management. The 
                                
                                전체 문서 읽기
                                
                            

이 제품과 관련된 검색 알림